GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper peptide found in human plasma, saliva, and urine
With a strong success rate in qualified patients, were committed to innovative, yet safe programs
Gastrointestinal effects are experienced by a significant proportion of patients, particularly during dose initiation and escalation: Nausea (affecting up to 20% of patients) is typically most pronounced in the first few weeks and often diminishes with continued use [10] [11] Diarrhoea or constipation may occur as the digestive system adjusts to slower gastric emptying Abdominal discomfort, bloating, or indigestion are common but usually mild Vomiting occurs less frequently but may necessitate dose adjustment These gastrointestinal symptoms can be minimised by eating smaller, more frequent meals, avoiding high-fat foods, and ensuring adequate hydration
Moreover, cancer cells that are resistant to radiation and chemotherapy have elevated GSH levels, probably due to GSHs ability to quench the ROS generated by these therapies [199]
